Implant Sciences Signs Cooperative Research & Development Agreement With TSL S&T

• Quantum Sniffer(TM) QS-B220 Explosives and Narcotics Trace Detector Selected for TSL Technology Optimization Partnership

Wilmington, MA - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced that its Quantum Sniffer(TM) QS-B220 benchtop explosives trace detector has been approved to partner with the developmental test and evaluation group of the Transportation Security Laboratory (TSL) in order to optimize the QS-B220 detection technology. TSL is a Department of Homeland Security Federal Laboratory within the DHS Science and Technology Directorate (S&T), located at the William J. Hughes Technical Center, Atlantic City International Airport, New Jersey.

Implant Sciences has signed a Cooperative Research and Development Agreement (CRADA) with DHS S&T TSL to officially begin its technology optimization.

DHS S&T/TSL's core mission is to enhance homeland security, including the research, development and validation of solutions to detect and mitigate the threat of improvised explosive devices (IEDs). DHS S&T establishes CRADAs as public-private partnerships designed to expeditiously mature and deploy security technologies and to prepare products to achieve Transportation Security Administration (TSA) certification/qualification. TSA certified products may be used at ports of entry across the U.S., including airports.

Implant Sciences' Vice President of Technology, Todd Silvestri stated, "The insight of the professionals at TSL will be invaluable in preparing the QS-B220 to meet TSA's expectations. TSL brings extensive experience and expertise to the table which will help us build a better product."

"We are proud to be able to work with S&T to optimize our technology. This is a great example of a private-public partnership that helps save money for taxpayers while improving security in the United States," concluded Implant Sciences' President and CEO, Glenn D. Bolduc.